Actuate Therapeutics Inc
$2.11
-4.5%Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -5.8).
Valuation inputs: P/E -5.8, earnings yield N/A, momentum -4.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -2.8%, ROIC -2.7%).
Profitability stack: net margin 0.0%, ROE -2.8%, ROIC -2.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +43.5%, momentum -4.5%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Actuate Therapeutics Inc Market vs Earnings Trajectory
Loading price and EPS data...
Actuate Therapeutics Inc Fair Value Envelope
No Revenue Data
ACTU has not reported any revenue values in the available annual periods.
Actuate Therapeutics Inc Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ACTU has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ACTU has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ACTU has not reported any net profit margin values in the available annual periods.
Actuate Therapeutics Inc Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Actuate Therapeutics Inc Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Actuate Therapeutics Inc Street Expectations Map
Wall Street analysts project that ACTU stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 21.00, with estimates ranging from a low of 21.00 to a high of 21.00.
The consensus 1-year price target stands at 21.00, with estimates ranging from a low of 21.00 to a high of 21.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Actuate Therapeutics Inc Insider Positioning
During the last 12 months, insiders have purchased $1.50M and sold $1.62M worth of ACTU shares, resulting in $124K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
280.0K
1.62M
-1.6M
-$1.62M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
214.3K
1.50M
0
0.00
+1.5M
+$1.50M
Top Buyers
Kreis Leslie W.
Director, 10 Percent Owner:
$500K
Bios Equity Cof, Lp
Director, 10 Percent Owner:
$500K
Fletcher Aaron G.L.
Director, 10 Percent Owner:
$500K
Top Sellers
Thomson Todd S
Director, 10 Percent Owner:
$1.62M
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $124K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
No Dividend Yield Data
ACTU has not reported any dividend yield values in the available annual periods.
actu Dividend History
Learning Layer
Related Guides
Build conviction on ACTU by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.